Publication | Closed Access
Cytomegalovirus reactivation after bortezomib treatment for multiple myeloma and light chain amyloidosis
16
Citations
17
References
2019
Year
This study suggests that there is a substantial risk of CMV reactivation in CMV-seropositive plasma cell dyscrasia patients treated with bortezomib.
| Year | Citations | |
|---|---|---|
Page 1
Page 1